KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $5.3 billion.

  • AbbVie's Cost of Revenue rose 2592.59% to $5.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 billion, marking a year-over-year decrease of 90.05%. This contributed to the annual value of $16.9 billion for FY2024, which is 1719.81% down from last year.
  • As of Q3 2025, AbbVie's Cost of Revenue stood at $5.3 billion, which was up 2592.59% from $4.3 billion recorded in Q2 2025.
  • AbbVie's 5-year Cost of Revenue high stood at $6.5 billion for Q3 2023, and its period low was $4.0 billion during Q1 2023.
  • In the last 5 years, AbbVie's Cost of Revenue had a median value of $4.2 billion in 2023 and averaged $4.5 billion.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 11694.13% in 2021, then crashed by 3505.01% in 2024.
  • AbbVie's Cost of Revenue (Quarter) stood at $4.3 billion in 2021, then decreased by 3.47% to $4.2 billion in 2022, then skyrocketed by 36.79% to $5.7 billion in 2023, then fell by 22.93% to $4.4 billion in 2024, then increased by 20.66% to $5.3 billion in 2025.
  • Its last three reported values are $5.3 billion in Q3 2025, $4.3 billion for Q2 2025, and $4.0 billion during Q1 2025.